[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100610977":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":11,"centralContacts":35,"locations":41,"responsibleParty":54,"collaborators":11,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":11,"eligibilityCriteria":62,"healthyVolunteers":58,"sex":63,"minAge":64,"maxAge":65,"enrollmentInfo":66,"targetDuration":11,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":11,"overallStatus":44,"whyStopped":11,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"Usynova Pharmaceuticals Ltd.","INDUSTRY",[8,14,17,20],{"label":9,"type":10,"description":11,"interventionNames":12},"dose level 1","EXPERIMENTAL",null,[13],"Drug: Tyk2 inhibitor",{"label":15,"type":10,"description":11,"interventionNames":16},"dose level 2",[13],{"label":18,"type":10,"description":11,"interventionNames":19},"dose level 3",[13],{"label":21,"type":22,"description":11,"interventionNames":23},"placebo","PLACEBO_COMPARATOR",[24],"Drug: Placebo",[26,31],{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":11},"DRUG","Tyk2 inhibitor","Specific dose of Tyk2 inhibitor on specific days",[9,15,18],{"type":27,"name":32,"description":33,"armGroupLabels":34,"otherNames":11},"Placebo","Specified dose of Placebo on specified days.",[21],[36],{"name":37,"role":38,"phone":39,"phoneExt":11,"email":40},"Yang Zhang","CONTACT","+8613636393195","yang_zhang@usynova.com",[42],{"facility":43,"status":44,"city":45,"state":11,"zip":11,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":11},"Shanghai Skin Disease Hospital","RECRUITING","Shanghai","China","CN",{"type":49,"coordinates":50},"Point",[51,52],121.45806,31.22222,{"lat":52,"lon":51},{"type":55,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100610977","a-study-to-evaluate-effectiveness-and-safety-of-a-tyk2-inhibitor-in-subjects-with-moderate-to-severe-plaque-psoriasis-100610977",false,"NCT07234591","A Study to Evaluate Effectiveness and Safety of a TYK2 Inhibitor in Subjects With Moderate to Severe Plaque Psoriasis","A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of a TYK2 Inhibitor in Subjects With Moderate to Severe Plaque Psoriasis","Inclusion Criteria:\n\n* Male and female, ages 18 to 70 years\n* Body weight \\>40 kg, body mass index (BMI) of 18 to 40 kg\u002Fm2\n* Clinical diagnosis of plaque psoriasis for ≥6 months before the Baseline visit\n* Women of childbearing potential (WOCBP) and males who are sexucally active must agree to follow instructions for method(s) of contraception.\n\nExclusion Criteria:\n\n* Diagnosed with non-plaque psoriasis\n* Previously received tyrosine kinase 2 (TYK2) inhibitors\n* Previously received other psoriasis treatments such as biological agents, immunoregulators, or hormonal drugs within a specific period before administration, and the investigator deems it may affect the immunity of the subjects\n* Has participated in any clinical trials within 30 days or 5 half-lives of the drug before the first administration, or currently undergoing visits for other clinical trials;\n* Has history of chronic disease that may affect the study, or acute or chronic severe infectious diseases, such as a history of active or inadequately treated latent tuberculosis infection, severe bone or joint infections within 6 months before screening, and other acute infectious diseases.\n* Has known or suspected skin or systemic autoimmune diseases other than psoriasis and psoriatic arthritis;\n* Other conditions that the investigator deems unsuitable for participation in this study.\n\nOther protocol defined inclusion\u002Fexclusion criteria could apply","ALL","18 Years","70 Years",{"count":67,"type":68},140,"ESTIMATED","INTERVENTIONAL",[71],"NA","A Study to evaluate efficacy and safety in subjects with moderate to severe Plaque Psoriasis treated with a TYK2 Inhibitor for 12 weeks",[74,75],"Plaque Psoriasis","Moderate to Severe Plaque Psoriasis","2025-11-14",{"date":78,"type":79},"2025-11-18","ACTUAL",{"date":81,"type":79},"2025-10-21",{"date":83,"type":68},"2026-05-30",{"name":5,"class":6},1]